Literature DB >> 15019030

Development and validation of a HPLC method for routine quantification of the decapeptide Cetrorelix in liposome dispersions.

Holger Grohganz1, Oliver Schläfli, Matthias Rischer, Martin Brandl.   

Abstract

The development and validation of an HPLC method for the quantification of the decapeptide Cetrorelix (acetyl-D-2-naphthylalanyl-D-4-chlorphenylalanyl-D-3-pyridylalanyl-seryl-tyrosyl-D-citrullyl-leucyl-arginyl-prolyl-d-alaninamide), a potent antagonist of the luteinising hormone-releasing hormone in liposome dispersions is described. An isocratic reversed phase method with UV-detection appeared most appropriate. Several detergents were tried to disrupt liposomes. Furthermore, detergents turned out to be useful, because they minimised unwanted loss of Cetrorelix due to adsorption to the vial surfaces. Triton X-100 was found most effective, while sodium cholate led to quantification problems. In the presence of 2.5% Triton X-100 calibration curves with a high degree of linearity were achieved in the desired range of 0.2-10 microg/ml. The limits of detection and quantification of Cetrorelix were calculated from the peak-to-noise ratio to be 11 and 37 ng/ml, respectively. The repeatability of the method in presence of phospholipid and Triton was good with relative standard deviations (R.S.D.) ranging from 0.8% (at 0.05 microg/ml) to 1.5% (at 0.2 microg/ml). The presence of liposomes at phospholipid contents of up to 0.25mg/ml did not significantly affect the slope or linearity of the calibration curve, nor the peak-to-noise ratio.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15019030     DOI: 10.1016/j.jpba.2003.11.010

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  1 in total

1.  Development and Validation of a Reversed-phase HPLC Method for Assay of the Decapeptide Cetrorelix Acetate in Bulk and Pharmaceutical Dosage Forms.

Authors:  Shirin Hooshfar; Seyed Alireza Mortazavi; Mohammad Piryaei; Hossein Ramandi Darzi; Nahid Shahsavari; Farzad Kobarfard
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.